Table 2.
Demographic, clinical, and MRI data of the atrophy cohort.
| Total atrophy cohort | p-values total atrophy cohort BL vs. 3yr FU | IRL patients atrophy cohort | Non-IRL patients atrophy cohort | p–values IRL vs. Non-IRL | p–values non-IRL BL vs. 3yr FU | |
|---|---|---|---|---|---|---|
| Number of analyzed patients | 13 | 8 | 5 | |||
| Gender (f/m) | 7/6 | 5/3 | 2/3 | |||
| Number of IRL (f/m) | 58 | 37/21 | – | |||
| Age, years; median (range) | 45 (22–53) | 49.5 (25–53) | 30 (22–49) | |||
| Disease duration, years; median (range) | 11 (5–19) | 12.5 (5–19) | 11 (6–16) | |||
| Disease course (RRMS/SPMS) | 13/0 | 8/0 | 5/0 | |||
| EDSS; median (range) | ||||||
| Baselinea | 1.5 (0–2.5) | 1.5 (0–2.5) | 1.5 (0–2.5) | |||
| 3yr FUa | 2 (0.2.5) | 1.75 (0–2.5) | 2 (0–2.5) | |||
| MSSS; median (range) | ||||||
| 3yr FUa | 1.4 (0.1–3.5) | 1.4 (0.2–2.1) | 2.8 (0.1–3.5) | |||
| Lateral ventricles, ml; mean (STD) | ||||||
| Baselinea | 20.6 (7.1) | 0.012 | 22.6 (8.2) | 17.3 (3.5) | 0.045 | |
| 3yr FUa | 22.2 (8.4) | 24.1 (9.8) | 19.1 (4.8) | |||
| Thalamus, ml; mean (STD) | ||||||
| Baselinea | 15 (2.4) | 0.021 | 14.03 (2.5) | 16.5 (1.0) | 0.045 | |
| 3yr FUa | 14.8 (2.8) | 13.97 (2.5) | 16.2 (0.9) | 0.045 | ||
| Caudate nucleus, ml; mean (STD) | ||||||
| Baselinea | 6.6 (1.0) | 6.7 (1.2) | 6.5 (0.7) | |||
| 3yr FUa | 6.6 (1.1) | 6.7 (1.3) | 6.5 (0.6) | |||
| Putamen, ml; mean (STD) | ||||||
| Baselinea | 8.33 (1.25) | 0.043 | 8.1 (1.4) | 8.7 (1.0) | 0.038 | |
| 3yr FUa | 8.29 (1.26) | 8.0 (1.4) | 8.6 (1.0) | |||
| Pallidum, ml; mean (STD) | ||||||
| Baselinea | 2.8 (0.3) | 2.8 (0.4) | 2.8 (0.3) | |||
| 3yr FUa | 2.8 (0.3) | 2.8 (0.3) | 2.8 (0.3) |
Volume data are given as mean (STD), all other parameters as median (range).
a
Values refer to the time point of the MRI scan at baseline and 3yr FU.
The p-values < 0.05 indicate significant results and are shown in brackets. Significant results are marked in boldface. BL, baseline; EDSS, Expanded Disability Status Scale; f, female; FLAIR, Fluid-attenuated inversion recovery; FU, follow-up; IRL, iron rim lesion; m, male; MP2RAGE, Magnetization Prepared RApid Gradient Echo; ml, milliliter; MSSS, Multiple Sclerosis Severity Score; r, range; RRMS, relapsing-remitting multiple sclerosis; SDMT: Symbol Digit Modality Test; SPMS, secondary progressive multiple sclerosis; yr, year.